Cooper Companies (COO) is back in focus after reporting record quarterly revenue and an earnings beat, while largely resolving fertility media litigation and reiterating full year guidance that aligns with earlier expectations.

The earnings surprise and litigation progress have triggered a sharp short term rebound, with a 7 day share price return of 15.35% and 30 day share price return of 14.37%. However, overall momentum is still weak given the year to date share price decline of 15.40% and 3 year total shareholder return decline of 23.58%.

If strong healthcare execution is on your radar, it might be worth scanning a wider field and seeing what stands out in the 39 healthcare AI stocks

With record revenue, an earnings beat, buybacks and most fertility media litigation addressed, Cooper Companies now trades below some analyst valuation estimates. Is this a discounted entry point, or is the stock already pricing in future growth?

Most Popular Narrative: 21.3% Undervalued

At a last close of $68.62 versus a narrative fair value of $87.14, the current price sits well below what this widely followed model implies, putting the spotlight squarely on the earnings and cash flow story that underpins that gap.

Free cash flow is poised to inflect higher as a multi-year capital expenditure cycle winds down following the ramp-up of MyDAY capacity, with management guiding for approximately $2 billion in free cash flow over the next three years. This improved cash generation, tied to strong cost discipline and revenue momentum, will further benefit shareholders via debt reduction and share repurchases.

Curious how a slower revenue growth profile can still feed into strong earnings expansion and a higher fair value? The narrative leans heavily on widening margins, rising free cash flow and a lower future earnings multiple to bridge the gap between today’s price and its long term target.

Result: Fair Value of $87.14 (UNDERVALUED)

However, this depends on MyDAY gaining traction and on fertility and PARAGARD markets stabilising. Any prolonged weakness in these areas could quickly challenge that undervalued story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View: High P/E Puts Pressure On The Upside Story

While the narratives and some models point to upside, the current P/E of 56.8x is well above the peer average of 23x and the US Medical Equipment industry at 25.2x, and also above a fair ratio of 32.6x. That rich multiple leaves less room if growth or margins fall short.

For a closer look at how the numbers line up against this richer pricing, including how far the P/E could move toward the fair ratio, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on value and risks, it may be helpful to review the details yourself and move quickly to form your own view by checking the 2 key rewards and 1 important warning sign

Looking for more investment ideas?

If you are serious about building a stronger portfolio, do not stop at one stock. Use targeted screeners to find opportunities that others might be ignoring.

• Target potential mispricings by scanning companies that look cheap relative to quality using the 46 high quality undervalued stocks
• Strengthen your income stream by focusing on companies with higher yields and resilient payouts through the 9 dividend fortresses
• Prioritise resilience and sleep-at-night holdings by searching for companies with lower risk profiles in the 63 resilient stocks with low risk scores

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.